Why Apogee Therapeutics, Inc.’s (APGE) Stock Is Up 46.81%
As of Monday, June 22, Apogee Therapeutics, Inc.’s APGE share price has surged by 46.81%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Apogee Therapeutics, Inc.’s (APGE) Stock Is Up 46.77%
As of Monday, June 22, Apogee Therapeutics, Inc.’s APGE share price has surged by 46.77%, which has investors questioning if this is right time to sell.Omar Beirat
Why Apogee Therapeutics, Inc.’s (APGE) Stock Is Up 5.68%
As of Wednesday, June 17, Apogee Therapeutics, Inc.’s APGE share price has surged by 5.68%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Apogee Therapeutics, Inc.’s (APGE) Stock Is Up 5.45%
As of Thursday, June 04, Apogee Therapeutics, Inc.’s APGE share price has surged by 5.45%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Apogee Therapeutics, Inc.’s (APGE) Stock Is Up 5.15%
As of Wednesday, June 03, Apogee Therapeutics, Inc.’s APGE share price has surged by 5.15%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | APGE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10,067.3 | $252.6 | 77% |
|
| Shares Out (Mil) | 69.7 | 52.3 | 55% |
|
| Institutional Ownership | 97.4% | 92.1% | 74% |
|
| Float (Mil) | 58.1 | 40.2 | 51% |
|
| Beta | 0.69 | 0.95 | 40% |
|
| Avg Daily Volume (000s) | 954 | 455 | 70% |
|
| Price Change (52-week) |
256.5% | 52.9% | 98% |
|
| Growth | APGE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 12 | 12 | |
| Current EPS | ($0.961) | ($4.413) | ($5.188) | |
| Month Ago EPS | ($0.961) | ($4.413) | ($5.188) | |
| # Rev Up | 3 | 1 | 1 | |
| # Rev Down | 3 | 0 | 0 | |
| Three Months Ago EPS | ($1.184) | ($4.814) | ($5.428) | |
| Year/Year Chg | (9.7%) | 4.7% | 46.2% | |
| Financials | APGE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($275) | ($43) | 5% |
|
| EPS (TTM) | ($4.321) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($235) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $345 | $5 | 88% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $5 | 24% |
|
| Enterprise Value (Q1) (Mil) | $5,090 | $180 | 63% |
|
| Valuation | APGE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.95 | 2.56 | 87% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | APGE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (27.4%) | (49.8%) | 18% |
|
| ROE | (28.5%) | (55.5%) | 21% |
|
| Liabilities to Assets | 2.9% | 30.3% | 1% |
|
| F-Score | 3 | 3 | 19% |
|
Apogee Therapeutics, Inc. did not pass any screens on 7/31/2026.
